DDInter944 DDInter1619
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome . In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethambutol
Ethambutol {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Paclitaxel {u} (Compound) downregulates {v} (Gene) MLLT11
MLLT11 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) upregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Levodopa {u} (Compound) palliates {v} (Disease) restless legs syndrome
restless legs syndrome {u} (Disease) is palliated by {v} (Compound) Ropinirole
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol and Ethambutol (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Ropinirole (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel (Compound) downregulates MLLT11 (Gene) and MLLT11 (Gene) is upregulated by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) upregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) palliates restless legs syndrome (Disease) and restless legs syndrome (Disease) is palliated by Ropinirole (Compound)